TY - JOUR
T1 - Long-term health-related quality of life in patients with advanced esophagogastric cancer receiving first-line systemic therapy
AU - Pape, Marieke
AU - Vissers, Pauline A. J.
AU - Slingerland, Marije
AU - Haj Mohammad, Nadia
AU - van Rossum, Peter S. N.
AU - Verhoeven, Rob H. A.
AU - van Laarhoven, Hanneke W. M.
N1 - Funding Information: The authors thank the registration team of the Netherlands Comprehensive Cancer Organisation (IKNL) for the collection of data for the Netherlands Cancer Registry. Furthermore, the authors thank all participating patients for filling out the questionnaires and all hospitals that included patients for the POCOP study: Admiraal de Ruyter Ziekenhuis, Amphia ziekenhuis, Amsterdam Universitair Medische Centra, Antonius Sneek ziekenhuis, Albert Schweitzer ziekenhuis, Antonie van Leeuwenhoek ziekenhuis, Bernhoven ziekenhuis, BovenIJ ziekenhuis, Bravis ziekenhuis, Catherina Ziekenhuis Eindhoven, Helmond Elkerliek ziekenhuis, Erasmus Medisch Centrum, Elisabeth-TweeSteden Ziekenhuis, Flevoziekenhuis, Gelre ziekenhuizen, HagaZiekenhuis, Ikazia ziekenhuis, Isala ziekenhuis, Jeroen Bosch ziekenhuis, Leiden University Medical Center, Maasstad ziekenhuis, Martini ziekenhuis, Medisch Centrum Leeuwarden, Meander Medisch Centrum, Máxima Medisch Centrum, Maastricht Universitair Medisch Centrum Plus, Nij Smellinghe ziekenhuis, Noordwest Ziekenhuisgroep, R. de Graaf ziekenhuis, Radboudumc, Rijnstate ziekenhuis, Rode Kruis Ziekenhuis, St Jans Gasthuis Weert, Slingeland ziekenhuis, Spaarne ziekenhuis, St. Anna ziekenhuis, St. Antonius ziekenhuis, St. Jansdal ziekenhuis, Tjongerschans ziekenhuis, Universitair Medisch Centrum Utrecht, VieCuri Medisch Centrum, Weel-Bethesda ziekenhuis, Ziekenhuisgroep Twente, Zuyderland Medisch Centrum, and ZorgSaam Zorggroep Zeeuws-Vlaanderen. Funding Information: This work was supported by Bristol Myers Squibb (CA209-77E). The funder has financed part of the data collection for the Netherlands Cancer Registry. The corresponding author had full access to all the data in the study. Publisher Copyright: © 2023, The Author(s).
PY - 2023/9/1
Y1 - 2023/9/1
N2 - Purpose: To investigate the effect of systemic therapy on health-related quality of life (HRQoL) in patients with advanced esophagogastric cancer in daily clinical practice. This study assessed the HRQoL of patients with esophagogastric cancer during first-line systemic therapy, at disease progression, and after progression in a real-world context. Methods: Patients with advanced esophagogastric cancer (2014–2021) receiving first-line systemic therapy registered in the Prospective Observational Cohort Study of Oesophageal-gastric cancer (POCOP) were included (n = 335). HRQoL was measured with the EORTC QLQ-C30 and QLQ-OG25. Outcomes of mixed-effects models were presented as adjusted mean changes. Results: Results of the mixed-effect models showed the largest significant improvements during systemic therapy for odynophagia (− 18.9, p < 0.001), anxiety (− 18.7, p < 0.001), and dysphagia (− 13.8, p < 0.001) compared to baseline. After progression, global health status (− 6.3, p = 0.002) and cognitive (− 6.2, p = 0.001) and social functioning (− 9.7, p < 0.001) significantly worsened. At and after progression, physical (− 9.0, p < 0.001 and − 8.8, p < 0.001) and role functioning (− 15.2, p = 0.003 and − 14.7, p < 0.001) worsened, respectively. Trouble with taste worsened during systemic therapy (11.5, p < 0.001), at progression (12.0, p = 0.004), and after progression (15.3, p < 0.001). Conclusion: In general, HRQoL outcomes in patients with advanced esophagogastric cancer improved during first-line therapy. Deterioration in outcomes was mainly observed at and after progression. Implications for cancer survivors: Identification of HRQoL aspects is important in shared decision-making and to inform patients on the impact of systemic therapy on their HRQoL.
AB - Purpose: To investigate the effect of systemic therapy on health-related quality of life (HRQoL) in patients with advanced esophagogastric cancer in daily clinical practice. This study assessed the HRQoL of patients with esophagogastric cancer during first-line systemic therapy, at disease progression, and after progression in a real-world context. Methods: Patients with advanced esophagogastric cancer (2014–2021) receiving first-line systemic therapy registered in the Prospective Observational Cohort Study of Oesophageal-gastric cancer (POCOP) were included (n = 335). HRQoL was measured with the EORTC QLQ-C30 and QLQ-OG25. Outcomes of mixed-effects models were presented as adjusted mean changes. Results: Results of the mixed-effect models showed the largest significant improvements during systemic therapy for odynophagia (− 18.9, p < 0.001), anxiety (− 18.7, p < 0.001), and dysphagia (− 13.8, p < 0.001) compared to baseline. After progression, global health status (− 6.3, p = 0.002) and cognitive (− 6.2, p = 0.001) and social functioning (− 9.7, p < 0.001) significantly worsened. At and after progression, physical (− 9.0, p < 0.001 and − 8.8, p < 0.001) and role functioning (− 15.2, p = 0.003 and − 14.7, p < 0.001) worsened, respectively. Trouble with taste worsened during systemic therapy (11.5, p < 0.001), at progression (12.0, p = 0.004), and after progression (15.3, p < 0.001). Conclusion: In general, HRQoL outcomes in patients with advanced esophagogastric cancer improved during first-line therapy. Deterioration in outcomes was mainly observed at and after progression. Implications for cancer survivors: Identification of HRQoL aspects is important in shared decision-making and to inform patients on the impact of systemic therapy on their HRQoL.
KW - Esophageal cancer
KW - Gastric cancer
KW - Quality of life
KW - Treatment failure
UR - http://www.scopus.com/inward/record.url?scp=85168070037&partnerID=8YFLogxK
U2 - https://doi.org/10.1007/s00520-023-07963-5
DO - https://doi.org/10.1007/s00520-023-07963-5
M3 - Article
C2 - 37578590
SN - 0941-4355
VL - 31
JO - Supportive Care in Cancer
JF - Supportive Care in Cancer
IS - 9
M1 - 520
ER -